Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Nicole L. Kallewaard"'
Autor:
Himanshu P. Upadhyaya, Jenny Y. Chien, Amanda J. Long, Martin S. Bohm, Nicole L. Kallewaard, Lisa F. Macpherson, Dipak R. Patel, Matthew M. Hufford, Constance J. Krull, Jocelyn Y. Ang, Peter Chen, William J. Muller, Jeffrey A. Potts, Timothy Quinn, Mark Williams, BLAZE-1 Investigators
Publikováno v:
Infectious Diseases and Therapy, Vol 12, Iss 7, Pp 1861-1873 (2023)
Abstract Introduction Bamlanivimab and etesevimab (BAM + ETE) are monoclonal antibodies (mAbs) effective in reducing COVID-19-related hospitalizations and all-cause mortality in adult participants at increased risk for severe disease. We present phar
Externí odkaz:
https://doaj.org/article/4a8e4f959324473bb550800f3098224f
Autor:
Andrew Dippel, Austin Gallegos, Vineela Aleti, Arnita Barnes, Xiaoru Chen, Elizabeth Christian, Jared Delmar, Qun Du, Reza Esfandiary, Erika Farmer, Andrew Garcia, Qing Li, Jia Lin, Weiyi Liu, LeeAnn Machiesky, Neil Mody, Arun Parupudi, Meagan Prophet, Keith Rickert, Kim Rosenthal, Song Ren, Harini Shandilya, Reena Varkey, Kevin Wons, Yuling Wu, Yueh-Ming Loo, Mark T. Esser, Nicole L. Kallewaard, Sarav Rajan, Melissa Damschroder, Weichen Xu, Gilad Kaplan
Publikováno v:
mAbs, Vol 15, Iss 1 (2023)
ABSTRACTTo combat the COVID-19 pandemic, potential therapies have been developed and moved into clinical trials at an unprecedented pace. Some of the most promising therapies are neutralizing antibodies against SARS-CoV-2. In order to maximize the th
Externí odkaz:
https://doaj.org/article/9f5679dc1264437881b543ce3007dd81
Autor:
Kathryn Westendorf, Stefanie Žentelis, Lingshu Wang, Denisa Foster, Peter Vaillancourt, Matthew Wiggin, Erica Lovett, Robin van der Lee, Jörg Hendle, Anna Pustilnik, J. Michael Sauder, Lucas Kraft, Yuri Hwang, Robert W. Siegel, Jinbiao Chen, Beverly A. Heinz, Richard E. Higgs, Nicole L. Kallewaard, Kevin Jepson, Rodrigo Goya, Maia A. Smith, David W. Collins, Davide Pellacani, Ping Xiang, Valentine de Puyraimond, Marketa Ricicova, Lindsay Devorkin, Caitlin Pritchard, Aoise O’Neill, Kush Dalal, Pankaj Panwar, Harveer Dhupar, Fabian A. Garces, Courtney A. Cohen, John M. Dye, Kathleen E. Huie, Catherine V. Badger, Darwyn Kobasa, Jonathan Audet, Joshua J. Freitas, Saleema Hassanali, Ina Hughes, Luis Munoz, Holly C. Palma, Bharathi Ramamurthy, Robert W. Cross, Thomas W. Geisbert, Vineet Menachery, Kumari Lokugamage, Viktoriya Borisevich, Iliana Lanz, Lisa Anderson, Payal Sipahimalani, Kizzmekia S. Corbett, Eun Sung Yang, Yi Zhang, Wei Shi, Tongqing Zhou, Misook Choe, John Misasi, Peter D. Kwong, Nancy J. Sullivan, Barney S. Graham, Tara L. Fernandez, Carl L. Hansen, Ester Falconer, John R. Mascola, Bryan E. Jones, Bryan C. Barnhart
Publikováno v:
Cell Reports, Vol 39, Iss 7, Pp 110812- (2022)
Summary: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing monoclonal antibodies (mAbs) can reduce the risk of hospitalization from coronavirus disease 2019 (COVID-19) when administered early. However, SARS-CoV-2 variants of c
Externí odkaz:
https://doaj.org/article/daeff3ff2f814504a3643f35bb419fcf
Autor:
Lin Zhang, Josh Poorbaugh, Michael Dougan, Peter Chen, Robert L. Gottlieb, Gregory Huhn, Stephanie Beasley, Montanea Daniels, Thi Ngoc Vy Trinh, Melissa Crisp, Joshua Joaquin Freitas, Peter Vaillancourt, Dipak R. Patel, Ajay Nirula, Nicole L. Kallewaard, Richard E. Higgs, Robert J. Benschop
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
BackgroundNeutralizing monoclonal antibodies (mAbs) to SARS-CoV-2 are clinically efficacious when administered early, decreasing hospitalization and mortality in patients with mild or moderate COVID-19. We investigated the effects of receiving mAbs (
Externí odkaz:
https://doaj.org/article/2989bd8ebc794edc93eb3dcb73825ce6
Autor:
Sarah T. C. Elliott, Nicole L. Kallewaard, Ebony Benjamin, Leslie Wachter-Rosati, Josephine M. McAuliffe, Ami Patel, Trevor R. F. Smith, Katherine Schultheis, Daniel H. Park, Seleeke Flingai, Megan C. Wise, Janess Mendoza, Stephanie Ramos, Kate E. Broderick, Jian Yan, Laurent M. Humeau, Niranjan Y. Sardesai, Kar Muthumani, Qing Zhu, David B. Weiner
Publikováno v:
npj Vaccines, Vol 2, Iss 1, Pp 1-9 (2017)
Nucleic acid delivery: Instant, wide-ranging protection against influenza A and B A novel innoculation technique involving the injection of antibody-producing plasmid DNA has shown to be effective against influenza in mice. The flu is responsible for
Externí odkaz:
https://doaj.org/article/eacd8d537f1948d3bf6f77c99669bab8
Autor:
Andrew Dippel, Austin Gallegos, Vineela Aleti, Arnita Barnes, Xiaoru Chen, Elizabeth Christian, Jared Delmar, Qun Du, Reza Esfandiary, Erika Farmer, Andrew Garcia, Qing Li, Jia Lin, Weiyi Liu, LeeAnn Machiesky, Neil Mody, Arun Parupudi, Meagan Prophet, Keith Rickert, Kim Rosenthal, Song Ren, Harini Shandilya, Reena Varkey, Kevin Wons, Yuling Wu, Yueh-Ming Loo, Mark T. Esser, Nicole L. Kallewaard, Sarav Rajan, Melissa Damschroder, Weichen Xu, Gilad Kaplan
Publikováno v:
mAbs. 15(1)
To combat the COVID-19 pandemic, potential therapies have been developed and moved into clinical trials at an unprecedented pace. Some of the most promising therapies are neutralizing antibodies against SARS-CoV-2. In order to maximize the therapeuti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af952b124fb9afa4945e1f0ae2458177
https://pubmed.ncbi.nlm.nih.gov/36476037
https://pubmed.ncbi.nlm.nih.gov/36476037
Autor:
Gregory D. Huhn, Dipak R. Patel, Bharat Mocherla, Daniel Skovronsky, Kenneth L. Custer, Paul Klekotka, Imad Shawa, Andrew E. Schade, Janelle Sabo, Nicole L. Kallewaard, Michael Durante, Andrew C. Adams, Timothy R. Holzer, Ajay Nirula, Joseph Boscia, Masoud Azizad, Jose Cardona, Princy Kumar, Chad Crystal, Lei Shen, Peter Chen, Russell Perry, Corey Hebert, Richard E. Higgs, Robert L. Gottlieb, Matan C. Dabora, Philip J. Ebert, Jacob Van Naarden, Gerard J. Oakley, Jason Morris, Michael Dougan, Awawu Igbinadolor, Barry Heller
Publikováno v:
The New England Journal of Medicine
Background Patients with underlying medical conditions are at increased risk for severe coronavirus disease 2019 (Covid-19). Whereas vaccine-derived immunity develops over time, neutralizing monoclonal-antibody treatment provides immediate, passive i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::163d2b1d9fb708ea8c2b335a117a4a4b
https://doi.org/10.1056/nejmoa2102685
https://doi.org/10.1056/nejmoa2102685
Autor:
Robert J. Benschop, Jay L. Tuttle, Lin Zhang, Josh Poorbaugh, Nicole L. Kallewaard, Peter Vaillancourt, Melissa Crisp, Thi Ngoc Vy Trinh, Joshua J. Freitas, Stephanie Beasley, Montanea Daniels, Natalie Haustrup, Richard E. Higgs, Ajay Nirula, Myron S. Cohen, Mary Marovich
Publikováno v:
Science Translational Medicine. 14
As the coronavirus disease 2019 (COVID-19) pandemic evolves and vaccine rollout progresses, the availability and demand for monoclonal antibodies for the prevention and treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infecti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd9f68f454cedc7b05d5a1cba9ec8ef8
https://doi.org/10.1126/scitranslmed.abn3041
https://doi.org/10.1126/scitranslmed.abn3041
Autor:
Michael Dougan, Masoud Azizad, Peter Chen, Barry Feldman, Matthew Frieman, Awawu Igbinadolor, Princy Kumar, Jason Morris, Jeffrey Potts, Lauren Baracco, Lisa Macpherson, Nicole L. Kallewaard, Dipak R. Patel, Matthew M. Hufford, Linda Wietecha, Emmanuel Chigutsa, Sarah L. Demmon, Bryan E. Jones, Ajay Nirula, Daniel M. Skovronsky, Mark Williams, Robert L. Gottlieb
BACKGROUNDBebtelovimab is a potent, fully human IgG1 monoclonal antibody (mAb) targeting the S-protein of SARS-CoV-2, with broad neutralizing activity to all currently known SARS-CoV-2 variants of concern, including omicron variant lineages. Speciali
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8a89960690dccd85b26106e30598d68e
https://doi.org/10.1101/2022.03.10.22272100
https://doi.org/10.1101/2022.03.10.22272100
Autor:
Robert J. Benschop, Jay L. Tuttle, Lin Zhang, Josh Poorbaugh, Nicole L. Kallewaard, Peter Vaillancourt, Melissa Crisp, Thi Ngoc Vy Trinh, Joshua J. Freitas, Stephanie Beasley, Montanea Daniels, Natalie Haustrup, Richard E. Higgs, Ajay Nirula, Myron S. Cohen, Mary Marovich
As the COVID-19 pandemic evolves, and vaccine rollout progresses, the availability and demand for monoclonal antibodies for the prevention and treatment of SARS-CoV-2 infection are also accelerating. This longitudinal serological study evaluated the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7d2895870f014fbb0a170b38b846248e
https://doi.org/10.1101/2021.12.15.21267605
https://doi.org/10.1101/2021.12.15.21267605